



Supplementary Figure 5: Trametinib increases the intracellular accumulation of daunorubicin in KRAS-mutant CRC cells.

(A) Flow cytometric analysis demonstrating the effects of trametinib (T) and verapamil (Ve) on intracellular accumulation of daunorubicin (D) in CRC cell lines. Right: Overlay graphs representing intensities of intracellular daunorubicin in differently treated samples. Left: Bar graphs showing mean fluorescence intensity. All data are presented as mean \pm SEM. * $P < 0.05$ compared to daunorubicin alone, Student *t*-test. (B) Right: Representative immunofluorescence staining images of live CRC cells treated with daunorubicin alone (D), trametinib + daunorubicin (T+D), or verapamil + daunorubicin (Ve+D) showing increased accumulation of daunorubicin in the presence of trametinib. Scale bars = 50 μ m. Left: Quantification of corrected total cell fluorescence (CTCF). Data are presented as mean \pm SEM. * $P < 0.05$ compared to control, Student *t*-test.